How to Define and Manage Low-Risk Drug Allergy Labels
The Journal of Allergy and Clinical Immunology: In Practice · 2024-05 · 12 (5) · 1095-1106
DOI: 10.1016/j.jaip.2024.03.021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024-05. Verfasst von Ana Maria Copaescu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, VIC, Australia; Department of Medicine, Aus…. Hauptthemen laut MEDLINE: Drug Hypersensitivity. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, AHRQ HHS.
Abstract (Originalsprache)
Risk stratification in drug allergy implies that specific risk categories (eg, low, moderate, and high) classify historical drug hypersensitivity reactions. These risk categories can be based on reaction phenotypic characteristics, the timing of the reaction and evaluation, the required reaction management, and individual characteristics. Although a multitude of frameworks have been described in the literature, particularly for penicillin allergy labels, there has yet to be a global consensus, and approaches continue to vary between allergy centers. Immune-mediated drug allergies can sometimes be confirmed using skin testing, but a negative drug challenge is required to demonstrate tolerance and remove the allergy from the electronic health record ("delabel" the allergy). Even for quintessential IgE-mediated drug allergy, penicillin allergy, recent data reveal that a direct oral challenge, without prior skin testing, is an appropriate diagnostic strategy in those who are considered low-risk. Drug allergy pathogenesis and clinical manifestations may vary depending on the culprit drug, and as such, the optimal approach should be based on risk stratification that considers individual patient and reaction characteristics, the likely hypersensitivity reaction phenotype, the drug class, and the patient's clinical needs. This article will describe low-risk drug allergy labels, focusing on β-lactam and sulfonamide antibiotics, nonsteroidal anti-inflammatory drugs, iodinated contrast media, and common chemotherapeutics. This review will also address practical management approaches using currently available risk stratification and clinical decision tools.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, VIC, Australia; Department of Medicine, Austin Health, the University of Melbourne, Heidelberg, VIC, Australia; D…
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Wash.
- Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.
- Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, VIC, Australia; Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Inf…
Förderung
- NIAID NIH HHS
- AHRQ HHS
Zitieren
APA
Copaescu, A. M., Li, L., Blumenthal, K. G., & Trubiano, J. A. (2024). How to Define and Manage Low-Risk Drug Allergy Labels. The Journal of Allergy and Clinical Immunology: In Practice, 12(5), 1095-1106. https://doi.org/10.1016/j.jaip.2024.03.021
Vancouver
Copaescu AM, Li L, Blumenthal KG, Trubiano JA. How to Define and Manage Low-Risk Drug Allergy Labels. The Journal of Allergy and Clinical Immunology: In Practice. 2024;12(5):1095-1106. doi:10.1016/j.jaip.2024.03.021
BibTeX
@article{Copaescu2024,
author = {Copaescu, Ana Maria and Li, Lily and Blumenthal, Kimberly G and Trubiano, Jason A},
title = {How to Define and Manage Low-Risk Drug Allergy Labels},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2024},
volume = {12},
number = {5},
pages = {1095--1106},
doi = {10.1016/j.jaip.2024.03.021}
}
EUVIMED